Clinical bottom line
Cannabinoids show potential as adjunctive agents for pain management in orthopedic conditions such as osteoarthritis and fibromyalgia, with evidence suggesting analgesic benefits and improved symptom control. However, preclinical data indicate that certain cannabinoids may impair bone healing, raising safety concerns in fracture management. Current clinical evidence remains limited and heterogeneous, necessitating cautious use until further robust trials clarify efficacy, optimal formulations, dosing, and long-term safety (Ram et al., 2023; Karuppagounder et al., 2023; Khajuria et al., 2026).
What the evidence shows
Ram et al. (2023) provide a systematic narrative review highlighting advancements in fibromyalgia treatment, including cannabinoids. They report that cannabinoids may reduce pain intensity and improve quality of life, though study designs vary and placebo effects are notable.
Karuppagounder et al. (2023) investigate non-euphorigenic cannabis extracts in osteoarthritis models, demonstrating anti-inflammatory and analgesic effects without psychoactive side effects. These findings support cannabinoids as promising candidates for symptom relief in degenerative joint disease.
Khajuria et al. (2026) present a murine tibial fracture model study showing that cannabichromene attenuates fracture-associated pain but concurrently impairs bone repair processes. This dual effect underscores the complexity of cannabinoid use in orthopedic trauma and the need for balanced risk-benefit assessment.
Caveats and uncertainty
Clinical trials on cannabinoids for orthopedic pain often have small sample sizes, heterogeneous populations, and variable cannabinoid preparations.
Long-term safety data, particularly regarding bone metabolism and healing, are lacking.
Potential psychoactive effects and drug interactions require consideration.
Regulatory variability and product standardization issues limit generalizability.
Preclinical findings on bone repair impairment warrant caution in acute fracture settings.
How this may change practice
Clinicians may consider cannabinoids as adjuncts for chronic orthopedic pain syndromes such as osteoarthritis and fibromyalgia when conventional therapies are insufficient or contraindicated.
Use in acute fracture pain should be approached cautiously pending further safety data.
Patient education on potential benefits and risks is essential.
Monitoring for adverse effects and functional outcomes should accompany cannabinoid therapy.
Future guidelines may incorporate cannabinoids with clearer recommendations as evidence matures.